Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy.

Developmental medicine and child neurology - 1 Aug 2022

Zambon Alberto A, Ayyar Gupta Vandana, Ridout Deborah, Manzur Adnan Y, Baranello Giovanni, Trucco Federica, Muntoni Francesco

Abstract excerpt

AIM: To correlate the North Star Ambulatory Assessment (NSAA) and timed rise from floor (TRF) recorded at age of expected peak with age at loss of ambulation (LOA) in Duchenne muscular dystrophy (DMD). METHOD: Male children with DMD enrolled in the UK North Start Network database were included according to the following criteria: follow-up longer than 3 years, one NSAA record between 6 years and 7 years 6 months...

Topics

Join the communities discussing this publication.

Activities of Daily Living
Adrenal Cortex Hormones
Child
Genotype
Muscular Dystrophy, Duchenne

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 35385138
DOI: 10.1111/dmcn.15176
PMCID: PMC9303180

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy.PMID 35385138Read ↗

The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.Semantic proximity Read ↗

The impact of genotype on age at loss of ambulation in individuals with Duchenne muscular dystrophy treated with corticosteroids: A single-center study of 555 patients.Semantic proximity Read ↗

North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up.Semantic proximity Read ↗

Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls.Semantic proximity Read ↗

DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study.Semantic proximity Read ↗

Online Self-Report Data for Duchenne Muscular Dystrophy confirms natural history and can be used to assess for therapeutic benefitsSemantic proximity Read ↗

Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.Semantic proximity Read ↗

Genotype-related respiratory progression in Duchenne muscular dystrophy-A multicenter international study.Semantic proximity Read ↗

Association of Initial Maximal Motor Ability With Long-term Functional Outcome in Patients With COL6-Related Dystrophies.Semantic proximity Read ↗

A genome-wide association analysis of loss of ambulation in dystrophinopathy patients suggests multiple candidate modifiers of disease severitySemantic proximity Read ↗

Can symptomatic nmDuchenne carriers benefit from treatment with ataluren? Results of 193-month follow-up.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.